Skip to main content

Table 1 Clinical characteristics of participants from the Affy6.0 datasets (stage 1a)

From: Genome-wide association study identifies novel loci for type 2 diabetes-attributed end-stage kidney disease in African Americans

  WFSM FIND ARIC JHS MESA CARDIA
T2D-ESKD Non-diabetic non-nephropathy T2D-ESKD T2D-lacking nephropathy T2D-ESKD Non-diabetic non-nephropathy T2D-lacking nephropathy Non-diabetic non-nephropathy T2D-lacking nephropathy Non-diabetic non-nephropathy T2D-lacking nephropathy Non-diabetic non-nephropathy T2D-lacking nephropathy
N 790 891 627 299 96 1318 807 1569 343 774 278 747 165
Females (%) 63 56 54 76 65 62 63 59 68 54 53 60 66
Age (years) 62.1 ± 10.0 47.2 ± 11.8 56.84 ± 12.0 59.8 ± 11.1 68.2 ± 6.6 60.2 ± 6.1 60.3 ± 5.8 53.4 ± 11.6 59.3 ± 9.1 63.9 ± 9.2 65.6 ± 9.2 47.6 ± 5.0 49.4 ± 4.3
Age of onset of diabetes (years) 40.4 ± 11.8 47.3 ± 10.4 57.4 ± 10.8 - 44.9 ± 11.3 32.3 ± 7.9
Duration of diabetes prior to ESKD (years) 18.5 ± 9.6 20.5 ± 8.6
Duration of ESKD (years) 3.3 ± 3.6 0.6 ± 1.8
Fasting serum glucose (mg/dl) 193 ± 64 293 ± 115 105 ± 9 192 ± 94 90 ± 8 156 ± 66 98 ± 10 164 ± 59 96 ± 9 167 ± 66
eGFR (ml/min/1.73m2) - 96.7 ± 21.3 - 78.6 ± 12.5 79.5 ± 12.6 95.5 ± 17.6 92.7 ± 18.5 78.9 ± 12.1 82.9 ± 16.0 91.1 ± 13.1 95.6 ± 13.6
Body mass index (kg/m2) 29.8 ± 7.0 30.0 ± 7.0 33.4 ± 7.3 29.2 ± 6.1 32.2 ± 6.8 31.6 ± 7.7 35.4 ± 7.7 29.8 ± 5.8 31.8 ± 6.5
  1. Categorical data expressed as percentage; continuous data as mean ± SD
  2. Abbreviations: T2D type 2 diabetes, ESKD end-stage kidney disease, N number, eGFR estimated glomerular filtration rate